SAMD5 mRNA was overexpressed in prostate cancer and can predict biochemical recurrence after radical prostatectomy
- 5 Downloads
To identify a novel biomarker that can predict biochemical recurrence (BCR) after radical prostatectomy.
The gene expression profile of SAMD5 in prostate cancer was explored based on the oncomine database and The Cancer Genomic Atlas (TCGA). The follow-up information and clinical pathologic variables were extracted from the following cohort study: TCGA_prostate carcinoma. And then, survival analysis was conducted using the Kaplan–Meier plot and Cox’s proportional hazard regression model. Furthermore, another independent cohort study: Taylor prostate, was also acquired to validate the predictive effect of SAMD5 on BCR. In addition, the expression profile of SAMD5 in other cancer types was investigated using TCGA dataset.
SAMD5 mRNA was shown to be up-regulated in multiple microarray datasets of prostate cancer with the strict statistic criteria: p < 0.01 and fold change ≥ 2. In TCGA_PCa cohort study, high expression of SAMD5 was a risk factor for patients on post-operative BCR (HR 2.181, 95%CI 1.199–3.966, p = 0.011) and this predictive ability was independent of Gleason score and pathologic T stage (HR 2.018, 95%CI 1.102–3.698, p = 0.023). In another validating cohort study, the statistic trend was similar, and the pooled analysis by combining the two cohort study further confirmed its prognostic effect.
SAMD5 mRNA was overexpressed in prostate cancer and had powerful prognostic ability on predicting post-operative BCR, independent of Gleason score and pathologic T stage. Its high expression was associated with poor prognosis after RP.
KeywordsSAMD5 Biomarker Recurrence Prognosis Prostatic neoplasms
The Cancer Genomic Atlas
Gene expression profiling interactive analysis
Transcripts per million
American Joint Committee on Cancer
This research was based on public database: TCGA and GEPIA, and we are grateful for the extraordinary works of these project groups. We thank Bioinformatics Engineer Rang-Fei Zhu for his excellent pretreatment of TCGA-PCa data.
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Compliance with ethical standards
Conflict of interest
All the authors declare that they have no conflict of interest.
The patients’ information involved in our research were obtained from The Cancer Genome Atlas (TCGA) and Taylor Prostate dataset. All the patients and treatments complied with the principles laid down in the Declaration of Helsinki in 1964 and its later amendments or comparable ethical standards.
Informed consent was confirmed by all the patients participated in the TCGA-Prostate adenocarcinoma project and Taylor prostate project.
- 7.Watanabe T, Kobunai T, Akiyoshi T et al (2014) Prediction of response to preoperative chemoradiotherapy in rectal cancer by using reverse transcriptase polymerase chain reaction analysis of four genes. Dis Colon Rectum 57:23–31. https://doi.org/10.1097/01.dcr.0000437688.33795.9d CrossRefGoogle Scholar
- 13.Thompson IM, Andriole GL, Blumenstein B et al (2003) AJCC cancer staging manual, 6th edn. Springer, New YorkGoogle Scholar